Literature DB >> 9610529

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.

P M Ridker1, R J Glynn, C H Hennekens.   

Abstract

BACKGROUND: C-reactive protein (CRP) is a sensitive marker of inflammation, and elevated levels have been associated with future risk of myocardial infarction (MI). However, whether measurement of CRP adds to the predictive value of total cholesterol (TC) and HDL cholesterol (HDL-C) in determining risk is uncertain. METHODS AND
RESULTS: Among 14916 apparently healthy men participating in the Physicians' Health Study, baseline levels of CRP, TC, and HDL-C were measured among 245 study subjects who subsequently developed a first MI (cases) and among 372 subjects who remained free of cardiovascular disease during an average follow-up period of 9 years (controls). In univariate analyses, high baseline levels of CRP, TC, and TC:HDL-C ratio were each associated with significantly increased risks of future MI (all P values <0.001). In multivariate analyses, models incorporating CRP and lipid parameters provided a significantly better method to predict risk than did models using lipids alone (all likelihood ratio test P values <0.003). For example, relative risks of future MI among those with high levels of both CRP and TC (RR=5.0, P=0.0001) were greater than the product of the individual risks associated with isolated elevations of either CRP (RR=1.5) or TC (RR=2.3). In stratified analyses, baseline CRP level was predictive of risk for those with low as well as high levels of TC and the TC:HDL-C ratio. These findings were virtually identical in analyses limited to nonsmokers and after control for other cardiovascular risk factors.
CONCLUSIONS: In prospective data from a large cohort of apparently healthy men, baseline CRP level added to the predictive value of lipid parameters in determining risk of first MI.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610529     DOI: 10.1161/01.cir.97.20.2007

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  159 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis.

Authors:  J D Rutherford
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Heart disease and the inflammatory response.

Authors:  W Koenig
Journal:  BMJ       Date:  2000-07-22

3.  Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.

Authors:  Aram V Chobanian
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

Review 4.  Screening relatives of patients with premature coronary heart disease.

Authors:  Gilbert R Thompson
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

5.  Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation.

Authors:  P M Ridker
Journal:  Curr Cardiol Rep       Date:  2000-07       Impact factor: 2.931

Review 6.  C-reactive protein and risk of cardiovascular disease: evidence and clinical application.

Authors:  Paul M Ridker; Shari S Bassuk; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 7.  Interpretation of observational studies.

Authors:  P Jepsen; S P Johnsen; M W Gillman; H T Sørensen
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

8.  Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection.

Authors:  Emily S Ford; Jamieson H Greenwald; Aaron G Richterman; Adam Rupert; Lauren Dutcher; Yunden Badralmaa; Ven Natarajan; Catherine Rehm; Colleen Hadigan; Irini Sereti
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

9.  Relationship of five inflammatory gene polymorphisms with morbidity and mortality in 533 patients admitted to an ICU.

Authors:  Jan R Ortlepp; Jürgen Graf; Katharina Vesper; Fabian Schmitz; Vera Mevissen; Sebastian Sucigan; Alexander Kersten; Christian Weber; Uwe Janssens
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

10.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.